TalkMed Group Limited (SGX: 5G3)

Market Cap	543.93M
Revenue (ttm)	79.12M
Net Income (ttm)	28.30M
Shares Out	1.33B
EPS (ttm)	0.02
PE Ratio	19.73
Forward PE	n/a
Dividend	0.02 (5.43%)
Ex-Dividend Date	Aug 14, 2024

Volume	100
Open	0.410
Previous Close	0.405
Day's Range	0.410 - 0.410
52-Week Range	0.355 - 0.455
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About TalkMed Group

TalkMed Group Limited, an investment holding company, provides medical oncology, stem cell transplants, palliative care, and other related services in Singapore, China, Hong Kong, Vietnam, India, New Zealand, Australia, and the United States. It operates through two segments: Oncology Services; and Cellular and Gene Therapy Related Products and Services. The company offers medical oncology services in the areas of breast, colon, lung, liver, biliary and pancreatic, gastro-intestinal, head and neck, genitourinary and gynaecological, and haematol...

• Industry: Miscellaneous Health And Allied Services, Not Elsewhere Classified
• Founded: 1997
• Employees: 232
• Stock Exchange: Singapore Exchange
• Ticker Symbol: 5G3

Financial Performance

In 2023, TalkMed Group's revenue was 83.79 million, an increase of 9.39% compared to the previous year's 76.60 million. Earnings were 32.18 million, an increase of 5.33%.